Antoni Ribas, MD
Hematology & Oncology · Los Angeles, CANPI 1730109331
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (53.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 53.4% of the total. Reporting peaked in 2022 at $179,357 and has fallen 98.0% since, to $3,511 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $3429.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$169K
- Merck$50K
- F. Hoffmann-la Roche AG$26K
- Amgen$23K
- Sanofi US Services Inc.$17K
- Chugai Pharmaceutical Co., Ltd.$8K
- plus $22K from 10 others
Across 410 payments — averaging $30,939 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$8.8M
- Pfizer$738K
- Agilent Technologies, Inc.$712K
- GSK$628K
- Dynavax Technologies Corporation$602K
- Tesaro, Inc.$392K
- plus $837K from 9 others
What the payments were for
- Consulting fees$90,07629%
- Speaking & faculty fees$29,2339%
- Grants$168,58853%
- Travel & lodging$26,0358%
- Food & beverage$1,3890%
- Education$1580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $168,588 |
| Merck | 34 | $50,345 |
| F. Hoffmann-la Roche AG | 9 | $26,104 |
| Amgen | 20 | $23,356 |
| Sanofi US Services Inc. | 8 | $16,942 |
| Chugai Pharmaceutical Co., Ltd. | 5 | $8,395 |
| AstraZeneca | 1 | $5,000 |
| Jazz Pharmaceuticals Inc. | 2 | $4,544 |
| Gilead | 1 | $3,400 |
| Astrazeneca UK Limited | 2 | $1,765 |
| Almirall LLC | 1 | $1,650 |
| Pfizer | 1 | $1,500 |
| Roche Molecular Systems, Inc. | 2 | $1,400 |
| Novartis | 1 | $1,348 |
| Seagen Inc. | 1 | $1,125 |
| Array Biopharma Inc | 3 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$12,448
- KEYTRUDA$10,412
- Non-Covered Product$6,092
- Zelboraf$4,156
- ADCETRIS$1,125
- IMFINZI$665
- IMLYGIC$350
How this compares
$315,479 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
- Sandra HorningStanford$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.